Knowledgent is excited to participate in the upcoming DPharm: Disruptive Innovations to Advance Clinical Trials conference, now in its eighth year, happening September 25 & 26 in Boston! Continue reading Visit Knowledgent at DPharm 2018 in Boston
What gets me up in the morning is wanting to cure cancer and positively impact lives through the use of data and analytics. Our capabilities to try and test formulations exceed our ability to effectively analyze the results. Our use of real world evidence across populations in the 100s of millions allow us to potentially detect conditions that we have cured but not yet proven the cure.
For me this is essentially a classification problem. Part of the classification problem involves micro-populations. Another part of the classification problem involves meta-features.
Micro-populations are small cohorts differentiated by a bio-marker or a drug outcome. One micro-population taking a given drug might have very positive outcomes. Continue reading Micro-Populations and Meta-Features
“How can clients trust us with their money when we can’t even get their name right?” With statements like this, the business stakeholders at our client, a major financial services organization, expressed their frustration with the lack of consistency, accuracy, and completeness of their data.
How can you maximize ROI when you are trying to migrate your commercial sales platform to a new vendor? One of our pharmaceutical clients was recently grappling with this challenge, and we stepped in to help. In this video case study, Joe Theodore, who was Program Manager for this project, recounts how the Knowledgent team helped to reinvigorate this client’s commercial sales platform.
Strategic use of electronic patient health records provided by third parties is trending now in the pharmaceutical industry, particularly as a way to derive real-world insights and clinical outcomes. However, traditional relational databases often cannot handle these huge, unstandardized, and unstructured data sets.